BNET Industries

Vanda Pharmaceuticals Inc.

(VNDA) is in the Pharma Industry

Market Cap:$319.3M
Last Fiscal Year Sales:$1.7M
  • Public
  • US
Dow Jones Description

We are a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, with exclusive worldwide commercial rights to two products. We believe that each of our products will address a large market with significant unmet medical needs by offering advantages over currently available therapies. Our product portfolio includes: Fanapt tm (iloperidone), a compound for the treatment of schizophrenia. On November 27, 2007, the FDA accepted a New Drug Application (NDA) for Fanapt tm for the treatment of schizophrenia. On May 6, 2009, the FDA granted U.S. marketing approval of Fanapt tm for the acute treatment of schizophrenia in adults. We expect to commercialize Fanapt tm with our own sales force and/or commercial partners in the United States and to seek partners for commercialization of the compound outside of the United States. We plan to make Fanapt tm available in pharmacies in the United States prior to the end of 2009. Holders of an NDA have 60 days after approval to file for patent term restoration under the Hatch-Waxman Act. We submitted our application for patent term restoration with respect to Fanapt tm on June 9, 2009. On July 30, 2009, we signed a Medicaid Rebate Agreement with the Secretary of Health and Human Services relating to the sale of Fanapt tm to Medicaid patients. ...

Number of Employees 24
Contact Information

9605 Medical Center Dr Ste 300

Rockville, Maryland 20850-6380

vandapharma.com

(240) 599-4500

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • Vanda Pharma Says Deal With Novartis On Rights To Fanapt Becomes Effective - Quick Facts

    12/01/09 - Joint Venture / Alliance - View Story

  • Vanda Pharmaceuticals receives $200M in Novartis deal

    12/01/09 - New Investment - View Story

  • Vanda Pharmaceuticals Reports Third Quarter 2009 Results

    11/02/09 - Joint Venture / Alliance - View Story

  • New Schizophrenia drug set to debut in 2010

    11/02/09 - Merger / Acquisition - View Story

  • Vanda Pharmaceuticals Reports Third Quarter 2009 Results

    11/02/09 - Financial Announcement - View Story

  • Novartis Pharma Inks Pact with Vanda Pharmaceuticals for Commercialization of Fanapt in the U.S. and...

    10/14/09 - Joint Venture / Alliance - View Story

  • Week of Oct. 12, 2009: GSK and Prosensa Form Pact; Cardiokine Appoints CEO; More...

    10/14/09 - Joint Venture / Alliance - View Story

  • BioWatch: Baltimore biotech turns to the past for cutting-edge treatment

    10/17/09 - Joint Venture / Alliance - View Story

  • Vanda Inks $465M Novartis Deal, but Acquisition Not off the Table

    10/13/09 - Merger / Acquisition - View Story

  • Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009 --Conference Call...

    10/28/09 - Financial Announcement - View Story

  • Vanda Licenses Schizophrenia Drug To Novartis

    10/13/09 - Licensing / Contract - View Story

  • Novartis Enters Into Agreement for Exclusive US and Canadian Rights to FanaptTM, an FDA-Approved Oral...

    10/15/09 - Joint Venture / Alliance - View Story

  • Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of FanaptTM...

    10/15/09 - Joint Venture / Alliance - View Story

  • Vanda, Oculus, Sequenom: Biotech Notebook

    8/11/09 - Financial Announcement - View Story

News & Analysis

healthcare and vanda pharmaceuticals inc. - All News and Analysis

advertisement
Click Here
     VNDA $11.74 0.00 (0.00% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 1,004,810
Shares Outstanding 27.20M
Market Cap 319.4M
Year High 16.65
Year Low 0.45
Earnings Per Share -1.27
P/E Ratio -9.24
Dividend N/A
Yield N/A
IndustryTop Rated

Brought to you by CBS MoneyWatch.com

advertisement
Click Here